Interleukin-12 in Treating Patients With Cancer in the Abdomen

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 31, 1997

Primary Completion Date

October 31, 2001

Study Completion Date

October 31, 2001

Conditions
Anal CancerColorectal CancerGallbladder CancerGastric CancerPancreatic Cancer
Interventions
BIOLOGICAL

Recombinant Interleukin-12

Intraperitoneal over 30 minutes once weekly for 4 weeks, repeats every 4 weeks for up to 6 courses

Trial Locations (1)

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00003046 - Interleukin-12 in Treating Patients With Cancer in the Abdomen | Biotech Hunter | Biotech Hunter